Little Known Facts About AZD0156.
Kantarjian et al53 assessed the efficacy and protection of dasatinib, as as opposed with imatinib, for the primary-line therapy of CML-CP. Five hundred and nineteen clients with recently diagnosed CML-CP were randomly assigned to obtain dasatinib in a dose of one hundred mg as soon as day by day (259 sufferers) or imatinib at a dose of four hundred